Mikio Sugimoto

Professor

Kagawa University
Country flagJapan

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (12)

Year:

2026

Year:

2026

Local therapy is not considered a standard treatment option for patients with high-volume metastatic prostate cancer. Our research group’s previous retrospective study indicated potential benefits of local radiotherapy (LRT) for some high-volume metastatic prostate cancer patients, but prospective studies have yet to confirm these findings. We have thus planned a multicenter, open-label, randomized controlled phase III trial to confirm the efficacy of adding LRT to systemic hormonal therapy with androgen deprivation therapy plus an androgen receptor pathway inhibitor in a population of high-volume metastatic prostate cancer patients for whom the hormonal therapy is effective for 6 months. The primary endpoint is failure-free survival, defined as the time from randomization to prostate-specific antigen progression, radiological progression, clinical progression, or death from any cause. We aim to enroll 360 patients from 56 institutions over a 4-year period. This trial is registered at the Japan Registry of Clinical Trials (study no. jRCT1031220676).

Year:

2026

Objective To evaluate the incidence and clinical predictors of gastrointestinal and hepatic adverse events following oral administration of 5‐aminolevulinic acid hydrochloride (5‐ALA) before transurethral resection of bladder tumors (TURBT). Methods Safety data were analyzed from 145 patients enrolled in the prospective, single‐arm, multicenter phase III SPP2C102 trial who received 5‐ALA 4–8 h before TURBT. The incidence and severity of nausea, vomiting, and liver dysfunction, defined by elevations in aspartate aminotransferase, alanine aminotransferase, and/or gamma‐glutamyltransferase, were assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Potential risk factors were evaluated using univariable and multivariable logistic regression; results are reported as adjusted odds ratios (aOR) with 95% confidence intervals (CIs). Results Nausea/vomiting occurred in 28/145 patients (19.3%), all CTCAE grade 1–2. Female sex was independently associated (aOR 3.15, 95% CI 1.17–8.47), and diastolic blood pressure ≥ 80 mmHg showed a borderline association (aOR 2.37, 95% CI 0.99–5.78). Prophylactic antiemetics yielded a numerically lower rate (21.1% vs. 9.1%; p = 0.25). Liver‐enzyme elevations similarly occurred in 28/145 patients (19.3%), all CTCAE grade 1–2. Systolic blood pressure ≥ 130 mmHg remained independently associated (aOR 4.73, 95% CI 1.62–13.78), whereas associations for hypertensive comorbidity and BMI ≥ 25 kg/m 2 in univariable analyses did not persist after adjustment. Conclusion 5‐ALA–related nausea, vomiting, and transient liver‐enzyme elevations were common but generally mild. Simple bedside variables—particularly sex and blood pressure—may guide selective antiemetic prophylaxis and closer biochemical monitoring in routine practice.

Year:

2026

Year:

2026

Year:

2025

In the phase 3 PROpel trial (NCT03732820) patients with metastatic castration‐resistant prostate cancer (mCRPC) treated with olaparib plus abiraterone in the first‐line setting showed significantly prolonged radiographic progression‐free survival (rPFS; primary data cutoff [DCO]: 30 July 2021; hazard ratio [HR] 0.66, 95% confidence interval [CI], 0.54–0.81; p < 0.001), and at prespecified final OS analysis DCO (12 October 2022) numerically prolonged overall survival (OS; HR 0.81, 95% CI, 0.67–1.00; p = 0.054), versus placebo plus abiraterone for the global population. Here, we report efficacy, safety, and patient‐reported outcome data for the Asian subset in PROpel. Eligible patients were randomly assigned (1:1) to either olaparib (300 mg twice daily) or placebo in combination with abiraterone (1000 mg once daily). The primary endpoint was investigator‐assessed rPFS, and a key secondary endpoint was OS. In the Asian subset ( n = 133) at primary analysis, median rPFS was 27.6 months in the olaparib plus abiraterone arm ( n = 63), compared with 19.3 months in the placebo plus abiraterone arm ( n = 70; HR 0.55, 95% CI, 0.32–0.95). Median OS at the final analysis was not reached in the olaparib plus abiraterone arm versus 43.7 months in the placebo plus abiraterone arm (HR 0.59, 95% CI, 0.32–1.06). The safety profile was generally similar in the Asian subset and the global population. Efficacy and safety results for olaparib plus abiraterone in the Asian subset were generally consistent with the global PROpel population supporting the combination of olaparib plus abiraterone as an important first‐line treatment for consideration in Asian patients with mCRPC. Trial Registration: Clinicaltrials.gov identifier: NCT03732820

Year:

2025

Background With the shift in prostate cancer (PCa) diagnosis from systematic biopsies to magnetic resonance imaging (MRI)‐informed biopsies, we aimed to investigate the changing diagnostic practices of urologists and the impact of MRI on the detection of low‐risk PCa. Methods We conducted a retrospective analysis of 698 patients referred for PCa management at the Department of Urology, Kagawa University Hospital, between June 2014 and December 2023. Patients receiving dutasteride treatment ( n = 10) were excluded. We assessed longitudinal trends in patient age, PSA levels, utilization rates of digital rectal examination (DRE) and MRI, and the diagnosis of D'Amico low‐risk PCa. Predictive factors for low‐risk PCa diagnosis were also analyzed. Results The median age at diagnosis was 71 years (interquartile range [IQR], 66–76), and the median PSA level was 7.14 ng/mL (IQR, 5.29–12.07), both of which showed a significant upward trend over time (age: R 2 = 0.5687, p = 0.012; PSA: R 2 = 0.4076, p = 0.047). The frequency of DRE significantly decreased ( R 2 = 0.8306, p < 0.001), while MRI use increased significantly from 36.4% in 2014 to 92.1% in 2023 ( R 2 = 0.8960, p < 0.001). Concurrently, the proportion of D'Amico low‐risk PCa diagnoses declined from 22.7% in 2014 to 10.5% in 2023 ( R 2 = 0.6122, p = 0.008). Multivariate logistic regression revealed that MRI‐informed biopsies were significantly associated with a reduced likelihood of detecting low‐risk PCa (Odds ratio = 0.578, 95% confidence interval = 0.366–0.911, p = 0.018). Conclusion The increasing use of MRI‐informed biopsies in the diagnosis of PCa has shifted clinical practice, potentially contributing to the reduced detection of low‐risk PCa.

Year:

2025

Objective To evaluate the real-world clinical usage and effectiveness of apalutamide in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Methods We retrospectively reviewed the data of 186 men who received apalutamide across 17 institutions. The primary outcomes were the clinical usage of apalutamide for nmCRPC: prior usage of other androgen receptor signaling inhibitors (ARSIs), prior radical treatment, and the distribution of the prostate-specific antigen (PSA) doubling time (PSA-DT) at the initial administration of apalutamide. The secondary outcomes were the efficacy of apalutamide: PSA response (50% or 90% decline), progression-free survival, and skin-adverse events (AEs). Results We identified 75 patients with nmCRPC. A total of 31 (41.3%) patients received prior treatment with other ARSIs. A total of 42 men (56%) did not receive any prior radical treatment. The PSA-DT was <3.0, 3.0–5.9, 6.0–10, and > 10 months in 34.7%, 40%, 14.7%, and 10.6% of the patients, respectively. Patients receiving prior treatment with other ARSIs showed a significantly lower PSA response (PSA 50% decline, 88.4% vs. 18.8%; PSA 90% decline, 60.5% vs. 6.2%, P < .001, respectively) and significantly shorter progression-free survival (median: 37 months vs. 4 months; log-rank P < .001) than those without prior ARSI treatment, although cancer status did not differ between the groups. Skin-AEs were observed in 42.7%. Conclusions This real-world study revealed that apalutamide was used for the treatment after other ARSIs in >40% of patients with nmCRPC and showed limited efficacy in this context, although the effectiveness of apalutamide without prior other ARSI treatment was comparable with that reported in clinical trial results.

Year:

2025

Objectives To assess whether the coronavirus disease (COVID‐19) pandemic affected the outcomes of robot‐assisted radical prostatectomy (RARP) and urologists' treatment behaviors. Methods We retrospectively examined the medical records of 208 patients who had undergone RARP between August 2017 and December 2022. We compared the rate of preoperative androgen deprivation therapy (ADT), waiting period for RARP, patients' baseline characteristics and quality of life (QOL), proportion of adverse pathology on the RARP specimen, rate of Gleason grade group upgrading from biopsy to the RARP specimen, and prostate‐specific antigen (PSA) recurrence‐free survival between the pre‐pandemic and pandemic groups. Results The rate of preoperative ADT was significantly higher during than before the COVID‐19 pandemic (13.7% vs. 1.9%; p = 0.002). The baseline physical and mental QOL scores did not differ significantly between the groups. The proportion of D'Amico low‐risk patients was significantly lower (13.6% vs. 1.2%, p = 0.005) and waiting period for RARP was significantly shorter (median 3.5 months vs. 4.0 months, p = 0.016) in the pandemic group than in the pre‐pandemic group. There was no significant difference in the proportion of adverse pathology between the groups ( p = 0.104); however, the upgrading rate was significantly higher in the pre‐pandemic group ( p = 0.002). There was no significant difference in PSA recurrence‐free survival between the groups (log‐rank, p = 0.752). Conclusions The COVID‐19 pandemic did not adversely affect the oncologic outcomes of RARP and QOL before RARP. However, it caused urologists to increase the use of preoperative ADT and to reserve RARP for higher‐risk cases.

Year:

2024

Year:

2024

Year:

2024

Collaborators (8)

Yoshitaka Sekine

Gunma University

JAPAN
View details

Niven Mehra

Group Leader

Radboud University Medical Center

NETHERLANDS
View details

Toyonori Tsuzuki

-

JAPAN
View details

Masaki Shiota

Kyushu University

JAPAN
View details

Takuma Kato

Kagawa University

JAPAN
View details

Takahiro Kimura

Jikei University School of Medicine

JAPAN
View details

Young Deuk Choi

Professor

Yonsei University

SOUTH KOREA
View details

Keita Kobayashi

Yamaguchi University

JAPAN
View details